查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004208

DNA定序市場：2026-2032年全球市場預測（按服務類型、技術類型、樣本類型、應用和最終用戶分類）

DNA Sequencing Market by Offerings, Technology Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，DNA定序市場價值將達到 212.7 億美元，到 2026 年將成長至 257.2 億美元，到 2032 年將達到 836.9 億美元，年複合成長率為 21.61%。

主要市場統計數據
基準年 2025 212.7億美元
預計年份：2026年 257.2億美元
預測年份 2032 836.9億美元
複合年成長率 (%) 21.61%

2025年DNA定序現況：在政策和供應鏈變化中，從創新科學到可擴展的臨床實踐

DNA定序處於基礎科學、臨床診斷和數據驅動公共衛生三者的交匯點。到2025年，該領域將迎來轉折點，其應用範圍將從主要面向研究的技術擴展到臨床醫學、農業科學、環境監測和安全等領域。這項轉變的驅動力來自於讀取準確性、通量和工作流程自動化的持續改進，以及資訊科學的進步和監管及報銷環境的日趨成熟。

揭示正在重塑定序的變革性變化：長讀長定序、即時奈米孔定序、多體學、人工智慧生物資訊學和嚴格的臨床檢驗。

最顯著的變化在於各種定序模式在準確性、速度和成本方面的趨於一致，使得終端使用者能夠根據自身面臨的生物學挑戰而非傳統限制來選擇平台。合成短讀定序憑藉其高保真化學反應系統和能夠改善Q值分佈並減少對PhiX依賴性的軟體，正在拓展其臨床應用範圍，並簡化基於計數的檢測和全基因組分析。近期平台的更新增強了多體學功能，並提供了低通量單流池配置，在不犧牲數據品質的前提下降低了專業實驗室的進入門檻。這反映了一種更廣泛的趨勢，即根據實際樣本量和周轉需求來選擇合適的儀器。

評估 2025 年美國關稅對供應鏈定序、定價、跨境貿易和策略供應商多元化的累積影響。

2025年，貿易政策將成為定序買家成本、前置作業時間和平台選擇的主要決定因素。 2025年伊始，美國政府就面臨著持續實施的301條款措施以及2024年底宣布的對具有戰略意義的重要投入品加徵關稅的陰影。這些投入品包括鎢製品、晶圓和多晶矽等材料，將於2025年1月1日生效，並流入光學、微電子和特殊元件領域，這些領域廣泛用於設備、流動池和製造設備。雖然這些措施並非專門針對基因組學，但它們將對上游供應鏈和供應商定價產生連鎖反應。

整體而言，2025 年的這些關稅趨勢正在重塑品類層面的經濟格局：

雖然設備和平台的標價相對於運輸和安裝成本相對穩定，但當組件、光學元件或電子元件需要繳納關稅時，總擁有成本就會增加。採用單流池或其他小規模配置的供應商，無意中為買家提供了在預算週期不確定的情況下逐步提高產能的柔軟性。

解讀產品、技術、樣品、應用和最終用戶等關鍵細分市場洞察，從而更有信心地做出產品組合決策。

從產品線觀點來看，重點正從獨立儀器轉向基於化學、供應連續性和資訊學的整合系統。雖然儀器和平台定義了核心功能，但決定實際效用的因素正日益轉向耗材和試劑——例如，用於在樣本質量波動的情況下穩定文庫的酶和緩衝液，用於支持靶向或夥伴關係子測序的引物和探針，以及針對最新化學反應最佳化的全套測序試劑盒。服務正在重組為生命週期合作夥伴關係。具體而言，這些服務包括：合約定定序以應對臨時需求高峰；生物資訊學和數據分析服務，將原始數據（線索）轉化為臨床或研究報告；以及技術支援和維護，以確保儀器符合認證標準。軟體在整合整個系統中發揮核心作用，從機載鹼基識別到雲端原生二次分析和報告，並提供審計追蹤以滿足監管機構和支付方的要求。

當前主要區域趨勢：美洲、歐洲、中東、非洲和亞太地區將如何影響採用率、取得率和合規性？

區域趨勢既決定機會也決定風險。在美洲，美國正在引領臨床應用的趨勢。原定於2024年實施的加強監管、將檢查室自建檢測（LDT）納入醫療設備監管的舉措，於2025年3月被聯邦法院駁回，目前正被撤回，這既帶來了一絲慰藉，也帶來了一絲不確定性。儘管如此，許多醫院和診斷檢查室仍在加強其品管系統和文件記錄，他們預計聯邦政府和保險公司將在一定程度上主導標準化進程。同時，被譽為伴隨診斷的綜合基因組分析試劑盒正在推動腫瘤檢測向區域和地方中心分散化，尤其是在早期採用者證明了其營運可行性和符合保險公司要求的情況下。在加拿大和拉丁美洲市場，預算限制與群體基因組分析的雄心壯誌之間存在著平衡，當地服務供應商通常被用來應對關稅和外匯波動造成的成本波動。

主要企業提出的未來：平台藍圖、監管里程碑、夥伴關係以及圍繞臨床級工作流程的競爭。

近期公司層面的發展為我們了解競爭對手的未來走向提供了重要線索。其中一項最重要的公司里程碑事件是2024年中期完成的一項大規模資產剝離。此舉解決了監管方面的擔憂，使核心定序業務能夠重新專注於平台開發和臨床夥伴關係。此後，該供應商對其旗艦高通量產品線進行了升級，推出了單流式細胞選項、可提高產量並減少對PhiX依賴性的軟體版本，以及專為多組體學工作負載設計的新型試劑盒。此外，該公司還擁有獲得FDA已通過核准的綜合基因組分析試劑盒（體外診斷試劑盒，被譽為所有癌症的伴隨診斷試劑），這使得該公司能夠支持從學術機構到區域醫療系統的集中式和分散式腫瘤學模式。

為產業領導者提供的實用指導：降低供應風險、加速證據收集、協調合規性，並將定序創新轉化為成果。

首先，關稅應被視為長期因素，而非突如其來的衝擊。制定一個涵蓋設備、流動池和耗材的18-24個月滾動採購計劃，並納入基於情境的到貨成本模型，該模型應包含關於關稅稅率、運輸和安裝前置作業時間的明確假設。對於關鍵耗材（例如引子和探針、酵素和緩衝液以及定序盒），除了價格指數掛鉤定價外，還應尋找替代供應商，並協商在關稅區變更時觸發的應急條款。在臨床環境中，應調整安全庫存，使其與認證和驗證週期保持一致，以避免停機。

本執行摘要的編寫方法：採用嚴謹的調查方法，結合一手資料、監管審查和交叉檢驗的二手資料。

本執行摘要整合了透過混合方法收集的洞見，該方法著重於深度、三角驗證和可追溯性。主要研究包括對北美、歐洲和亞太地區的定序平台所有者、臨床實驗室主任、學術核心設施負責人、轉化研究人員、CRO高管和生物資訊架構師進行結構化和半結構化訪談。這些訪談重點在於平台選擇標準、使用改進試劑後的運作性能、驗證和認證實踐、關稅和出口管制帶來的採購限制，以及生物資訊學與電子健康記錄（EHR）之間不斷發展的合作。

總結整體情況：為什麼定序正在進入持續的實際應用階段，以及如何在波動和政策變化中做出明智的投資。

DNA定序已進入持續應用階段。這項科學日趨成熟，整合了各種平台、化學試劑和資訊學，建構出檢驗的工作流程，能夠以過去難以想像的速度和精確度解答臨床和研究問題。長讀長定序方法已與短讀長定序方法並駕齊驅，奈米孔定序平台正從現場應用擴展到規範化的工作流程，而全面的基因組分析也已克服監管方面的障礙，從而實現了腫瘤檢測的去中心化。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 DNA定序市場：依產品/服務分類

  • 耗材和試劑
    • 酵素和緩衝液
    • 引子和探針
    • 定序盒
  • 設備和平台
    • DNA定序儀
    • 樣品製備系統
    • PCR裝置
    • 流通池和濾芯硬體
  • 服務
    • 合約定序
    • 生物資訊學和數據分析服務
    • 技術支援和維護
  • 軟體

第9章：DNA定序市場：依技術類型分類

  • 次世代定序（NGS）
    • 合成定定序
    • 奈米孔定序
    • 離子半導體定序
  • 桑格定序
  • 第三代定序（TGS）
  • 表觀遺傳定序
    • 亞硫酸氫鹽定序
    • ChIP定序

第10章：依檢體類型分類的DNA定序市場

  • 人類檢體
    • 血
    • 唾液和口腔黏膜拭子
    • 尿
    • 細胞中的遊離DNA
    • 組織
    • 電漿
  • 動物檢體
  • 植物樣品
    • 葉子
    • 根
    • 種子
  • 微生物樣本
    • 細菌
    • 病毒
    • 真菌
    • 古菌
  • 環境樣品

第11章：DNA定序市場：依應用領域分類

  • 臨床診斷
    • 腫瘤學
    • 感染疾病的診斷
    • 罕見疾病和遺傳疾病的檢測
    • 生殖醫學和產前檢查
    • 新生兒篩檢
  • 出於研究目的
    • 基因組學和轉錄組學
    • 功能基因體學
    • 表觀遺傳學研究
  • 藥物發現和藥物開發
    • 生物標記發現
    • 伴隨診斷
    • 目標識別與檢驗
  • 農業基因組學
    • 植物育種和性狀發現
    • 作物病原體監測
  • 法醫學與安全
    • 個人識別
    • 刑事調查
    • 識別災難受害者
  • 環境與元基因組學研究

第12章 DNA定序市場：依最終用戶分類

  • 學術和研究機構
    • 政府附屬研究機構
    • 大學研究實驗室
  • 合約研究機構
  • 醫院和診斷檢查室
  • 製藥和生物技術公司

第13章：DNA定序市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 DNA定序市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 DNA定序市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國DNA定序市場

第17章：中國DNA定序市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Azenta, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • BioChain Institute Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eppendorf SE
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Genomics England
  • Genscript Biotech Corporation
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Macrogen Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Novogene Co, Ltd.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Sartorius AG
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-450A0628CCF5

The DNA Sequencing Market was valued at USD 21.27 billion in 2025 and is projected to grow to USD 25.72 billion in 2026, with a CAGR of 21.61%, reaching USD 83.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 21.27 billion
Estimated Year [2026] USD 25.72 billion
Forecast Year [2032] USD 83.69 billion
CAGR (%) 21.61%

Illuminating the state of DNA sequencing in 2025: from disruptive science to scalable clinical practice amid shifting policy and supply chains

DNA sequencing sits at the nexus of discovery science, clinical diagnostics, and data-driven public health. In 2025, the field has crossed a threshold from primarily research-oriented technology to a widening footprint in clinical care, agriscience, environmental surveillance, and security. This transition is powered by relentless improvements in read accuracy, throughput, and workflow automation, paired with better informatics and a maturing regulatory and reimbursement context.

At the same time, operating conditions are more complex than at any point in the last decade. Supply chains have been reshaped by tariffs and export controls, data flows are governed by evolving privacy regimes, and clinical validation standards are tightening even as some rules are being re-written by courts and legislators. These cross-currents demand that leaders rethink platform strategy, inventory policies, informatics architectures, and partnerships.

What differentiates the current landscape is that technology progress and policy dynamics are unfolding simultaneously. Sequencing chemistry and optics are leaping forward while long-read modalities gain clinical traction; nanopore platforms continue to improve raw read fidelity and real-time capabilities; and cloud-native bioinformatics is reducing time to answer for oncology, infectious disease, and population health. Meanwhile, regulatory milestones-from U.S. decisions on laboratory-developed tests to new European data rules-are redrawing the contours of clinical adoption. In short, competitive advantage now depends on integrating scientific, operational, and policy signals into coherent execution.

Unpacking transformative shifts reshaping sequencing: long reads, real-time nanopores, multiomics, AI bioinformatics, and rigorous clinical validation

The most consequential shift is the convergence of accuracy, speed, and cost across modalities, enabling end users to select platforms based on biological question rather than historical constraints. Short-read sequencing by synthesis has widened its clinical footprint with higher-fidelity chemistries and software that lift Q-score distributions and reduce PhiX dependency, streamlining counting-based assays and whole-genome runs. Recent platform updates have extended multiomic capability and offered lower-volume, single-flow-cell configurations that lower the hurdle for specialty labs without sacrificing data quality, reflecting a broader push to align instrument tiers with real-world sample volumes and turnaround needs.

Long-read adoption has accelerated from niche to pragmatic utility, particularly where structural variants, repeat expansions, phasing, and methylation matter. Clinical collaborators have reported rare-disease diagnostic gains using highly accurate long reads with integrated detection of complex variants and epigenetic signals, demonstrating potential to replace multi-step workups with a single comprehensive assay and to compress time to diagnosis. These efforts are paired with scaled operations-automated library prep and higher sample batching-that signal readiness for clinical-grade throughput.

Nanopore sequencing continues to blur the line between benchtop and field deployment. Chemistry and basecalling advancements have pushed single-molecule read fidelity into Q20 territory and above, while duplex strategies and software pipelines have tightened consensus accuracy. This has opened routine use of adaptive sampling for targeted enrichment and enabled near-telomere-to-telomere assemblies with simpler compute. Direct RNA improvements and quality-control applications for complex modalities such as mRNA have further broadened use cases in translational and manufacturing environments.

On the informatics side, two movements stand out. First, clinically oriented pipelines are shifting toward turnkey, cloud-delivered stacks with automated variant calling, annotation, and reporting embedded into laboratory information systems. Second, AI-assisted interpretation is being operationalized in tightly controlled workflows for oncology, infectious disease, and hereditary conditions. While AI governance remains in flux across jurisdictions, the direction of travel favors traceability, transparency, and auditability-features increasingly built into commercial bioinformatics offerings.

Regulatory and policy developments are equally transformative. In the United States, the Food and Drug Administration finalized a rule in 2024 that would have phased out general enforcement discretion for laboratory-developed tests over four years. However, a federal court ruling in March 2025 vacated the rule, and the agency has since moved to rescind it, resetting compliance timelines and prompting laboratories to recalibrate investment in submissions and quality systems. Even with this reversal, many organizations continue to align with device-grade documentation and post-market practices to future-proof operations against further policy changes.

Across the Atlantic, the European Health Data Space has entered into force and begins a multi-year transition to harmonize cross-border health data exchange while tightening governance of secondary use, including genetic and genomic data. For sequencing stakeholders, this sets the stage for interoperable data flows, stronger patient rights, and clearer pathways for research access-with meaningful implications for data localization, consent management, and partnerships with European data-access bodies.

Finally, clinical oncology has crossed an important threshold with the approval of comprehensive genomic profiling kits that include pan-cancer companion diagnostic indications. This milestone supports broader decentralization of tumor profiling into regional and community settings and strengthens the business case for in-house sequencing anchored by distributable kits and integrated informatics.

Assessing the cumulative impact of 2025 United States tariffs on sequencing supply, pricing, cross-border trade, and strategic vendor diversification

Trade policy has become a first-order determinant of cost, lead time, and platform choice for sequencing buyers in 2025. The year opened under the shadow of continued Section 301 actions and tariff increases on strategically important inputs announced in late 2024-covering materials such as tungsten products, wafers, and polysilicon effective January 1, 2025-that flow into optics, microelectronics, and specialty components found across instruments, flow cells, and manufacturing equipment. While not aimed specifically at genomics, these measures ripple through upstream supply chains and vendor pricing.

By spring, U.S. executive actions expanded the tariff landscape. A minimum global tariff regime and additional country-specific rates were unveiled, while separate Section 232 proclamations raised duties on steel and aluminum with short notice. Auto and auto-parts tariffs followed. Although these moves were justified under national security and reciprocity frameworks, they added uncertainty to procurement budgets and complicated landed-cost models for imported instruments and lab infrastructure. The administration also issued an order clarifying that overlapping tariff programs should not stack beyond intended policy goals, yet the practical effect for procurement teams has still been net complexity, with country-, category-, and timing-specific exceptions.

The summer brought further changes, including executive action to implement higher country-specific rates beginning in August, reinforcing the need for dynamic sourcing strategies. Suppliers with globally distributed production footprints and multiple distribution centers have been better positioned to buffer customers from shocks; nonetheless, end users have reported the need to widen approved vendor lists for critical consumables and to adjust inventory norms ahead of regulatory-sensitive clinical work.

The most conspicuous flashpoint for sequencing was geopolitical. In March, China banned imports of certain U.S. gene sequencing systems immediately after additional U.S. tariffs took effect, a move that not only limited a major manufacturer's access to a key market but also signaled the possibility of tit-for-tat actions affecting reagents and service workflows. For global labs with cross-border trial cohorts or manufacturing relationships in China, contingency planning moved from theoretical to operational.

Cumulatively, these 2025 tariff dynamics are reshaping category-level economics:

For instruments and platforms, list prices have held steadier than freight and installation costs, but total cost of ownership is rising where components, optics, or electronics are affected by duties. Vendors that introduced single-flow-cell and other lower-volume configurations have inadvertently given buyers more flexibility to stage capacity additions in uncertain budget cycles.

For consumables and reagents, tariffs amplify the value of multi-sourcing and local inventory buffers. Enzymes, buffers, primers, probes, and sequencing kits are susceptible to upstream cost swings in raw materials and packaging. Where import duties touch critical minerals or upstream wafer-based fabrication, knock-on effects can surface in consumable pricing even when final kit assembly is domestic.

For services, contract sequencing providers with diversified geographies can arbitrage tariffs by routing projects through facilities in lower-duty jurisdictions, while maintaining data residency where required. Bioinformatics and data analysis services-less exposed to physical trade-still feel tariff-adjacent effects through hardware import costs and cloud egress strategies that vendors adjust to protect margins.

For software, direct tariff effects are limited, but vendor negotiations increasingly bundle instrument, consumables, and analysis under value-based contracts to smooth duty-driven volatility. This tightens lock-in risk and elevates the importance of interoperability and exit clauses in master agreements.

Overlaying tariffs, the legislative trajectory of the BIOSECURE framework has moved from proposal to an amendment adopted by the U.S. Senate in the annual defense legislation, increasing the likelihood of restrictions on federally funded entities' use of specified foreign-adversary biotechnology firms. Even prior to final enactment, federal grantees are beginning to assess vendor exposure and to document supply-chain provenance-implications that reach sequencing instruments, kits, and data services sourced from or routed through China-affiliated firms.

The practical takeaway is straightforward: duty-driven cost and availability shocks are no longer episodic. Procurement strategies that assume stable tariffs will underperform. Leaders are responding by negotiating indexed pricing, adding regional service providers, increasing safety stocks for clinical-critical consumables, and modeling scenario-based total cost of ownership that incorporates variable duties, shipping, and installation windows.

Decoding key segmentation insights across offerings, technologies, samples, applications, and end users to guide high-confidence portfolio decisions

Viewed through the lens of offerings, the center of gravity continues to shift from standalone instruments toward integrated systems anchored by chemistry, supply continuity, and informatics. While instruments and platforms define core capability, the determinant of real-world utility is increasingly the consumables and reagents stack-enzymes and buffers that stabilize libraries under variable sample quality, primers and probes that support targeted or amplicon-based panels, and full sequencing kits optimized for updated chemistries. Services are being recast as lifecycle partnerships: contract sequencing for burst capacity, bioinformatics and data analysis services that translate raw reads into clinical or research reports, and technical support and maintenance that keep fleets validated under accreditation. Software now ties the system together, from onboard basecalling to cloud-native secondary analysis and reporting, with audit trails that satisfy regulators and payers.

Technologically, the market is no longer a binary short-read versus long-read choice but a toolkit. Next-generation sequencing remains the workhorse, with sequencing by synthesis leading high-throughput and mid-throughput labs, while ion semiconductor sequencing retains relevance in targeted applications that value speed and cost-predictable runs. Third-generation sequencing has stepped into mainstream consideration: long-read platforms are tackling structural variation, repeat expansions, and phasing at scale, and nanopore systems are adding real-time calling and on-instrument enrichment to workflows that once required extensive sample prep. Epigenetic sequencing is moving from research to clinical exploration, with bisulfite sequencing and ChIP sequencing increasingly paired with genomic reads to link sequence to regulation.

Sample diversity is broadening as users pursue comprehensive biology. Human samples-blood; saliva and buccal swabs; urine; cell-free DNA; tissue; and plasma-anchor clinical diagnostics and translational research, with cell-free DNA feeding liquid biopsy pipelines and tissue powering comprehensive genomic profiling. Animal samples now extend beyond model organisms to veterinary diagnostics and livestock genetics. Plant samples-leaf, root, and seed-support trait discovery and breeding programs under climate and pathogen pressure. Microbial samples-bacteria, viruses, fungi, and archaea-drive metagenomics in health, food safety, and industrial bioprocessing. Environmental samples-from wastewater to soil and air-are expanding surveillance and ecological studies.

Applications mirror this breadth. Clinical diagnostics is deepening across oncology, infectious disease diagnosis, rare disease and genetic disorder testing, reproductive health and prenatal testing, and newborn screening, with an emphasis on validated panels and clinical-grade workflows. Research applications still command significant share of activity-genomics and transcriptomics, functional genomics, and epigenetics research-now often combined in multiomic designs. Drug discovery and development users leverage sequencing for biomarker discovery, companion diagnostics, and target identification and validation. Agrigenomics is benefiting from routine plant breeding and trait discovery and from crop pathogen surveillance. Forensics and security continue to invest in human identification, criminal investigation, and disaster victim identification, while environmental and metagenomic studies are shifting from episodic projects to continuous monitoring programs.

End-user patterns reflect this segmentation. Academic and research institutions, including government research institutes and university labs, continue to pioneer novel protocols and large-scale studies that seed downstream clinical adoption. Contract research organizations provide elasticity for sponsors, especially as tariffs and lead times complicate internal capacity planning. Hospitals and diagnostic laboratories are investing in on-premise sequencing where validated kits and streamlined software reduce complexity, while remaining mindful of evolving rules for laboratory-developed testing. Pharmaceutical and biotechnology companies increasingly integrate sequencing across discovery and development, tying biomarker strategies to clinical trial design and companion diagnostic development.

Regional dynamics that matter now: how the Americas, Europe-Middle East-Africa, and Asia-Pacific will shape adoption, access, and compliance

Regional dynamics define opportunity and risk in equal measure. In the Americas, the United States sets the tone for clinical adoption. The 2024 regulatory push to bring laboratory-developed tests under device rules was halted by a federal court in March 2025 and is now being rescinded, injecting both relief and uncertainty. Many hospital and diagnostic laboratories are proceeding with strengthened quality systems and documentation anyway, anticipating that some level of federal or payer-driven standardization will endure. Meanwhile, comprehensive genomic profiling kits with companion diagnostic claims are catalyzing decentralization of oncology testing into community and regional centers, especially as the first wave of adopters demonstrates operational feasibility and payer alignment. Canada and Latin American markets are balancing budget constraints with population genomics ambitions, often leveraging regional service providers to manage cost volatility linked to tariffs and currency.

Across Europe, the Middle East, and Africa, policy clarity is improving due to the European Health Data Space. The regulation's phased implementation provides a roadmap for cross-border access to health data, governance of secondary use, and interoperability expectations for electronic health records. For genomics, the most immediate implications are investments in consent management, data access bodies, and trusted data holders-foundations that will affect how clinical and research sequencing data move within and beyond national borders. In practical terms, organizations planning multicenter studies or pan-European diagnostic offerings will need to align with the EHDS's timetables and technical frameworks. Middle Eastern genomics programs continue to scale capacity through national initiatives, while African centers of excellence build capability via consortia and public-private partnerships that emphasize training, infrastructure, and data sovereignty.

In Asia-Pacific, heterogeneity is the norm. Japan's regulatory environment has welcomed comprehensive genomic profiling tools with local approvals, reinforcing an ecosystem that values precision oncology and coordinated reimbursement policy. China remains a source of innovation and scale but features two-way geopolitical risk: domestic firms are ascendant, and policy actions on both sides of the Pacific have constrained trade in instruments and components, with 2025's import bans and export controls underscoring volatility. Elsewhere, Australia, South Korea, Singapore, and India continue to invest in research infrastructure and translational pipelines, frequently adopting hybrid sourcing models and cloud-forward informatics to manage geography and compliance.

What leading companies signal about the future: platform roadmaps, regulatory milestones, partnerships, and the race for clinical-grade workflows

Recent company-level developments offer a forward look at how competition will unfold. One of the most consequential corporate milestones was the completion of a major divestiture in mid-2024, which removed a regulatory overhang and allowed the core sequencing business to refocus on platform execution and clinical partnerships. The same supplier has since advanced its flagship high-throughput line with a single-flow-cell option, software releases that boost yield and reduce PhiX dependency, and new kits designed for multiomic workloads. Together with its FDA-approved comprehensive genomic profiling kit-an IVD with pan-cancer companion diagnostic claims-this positions the company to serve both centralized and distributed oncology models, from academic hubs to regional systems.

Long-read specialists have translated accuracy gains into clinical collaborations. Publicized studies with European academic medical centers using highly accurate long reads on next-generation instruments have shown that complex structural variants and methylation patterns can be captured alongside small variants, with diagnostic implications for challenging rare disease cases. In parallel, these vendors are scaling manufacturing and sample-throughput capabilities and winning large research awards that signal confidence in long-read modalities for population-scale projects that probe both genome and epigenome.

Nanopore platform providers are delivering continuous chemistry, basecalling, and software improvements that extend utility from field sequencing to regulated labs. Q20-class chemistry, duplex strategies trending toward even higher single-molecule accuracy, enhanced direct RNA runs, and routine adaptive sampling all feed into a broader thesis: real-time, long-fragment sequencing with flexible targeting can be made accessible to non-specialist labs. The steady cadence of technology updates, coupled with growing reference datasets and improved workflows for assembly and targeted calling, is narrowing the performance gap with other modalities while preserving unique advantages in speed and portability.

Challenger short-read vendors are pressing on value and openness. New instruments and chemistry upgrades focus on reducing run cost per read, opening large-scale projects to more institutions and service providers. Some entrants emphasize compatibility with existing library prep and analysis ecosystems, while cultivating certified service networks that offer immediate access without capital outlay-an attractive proposition in tariff-inflated budget cycles.

Across the ecosystem, content suppliers and automation providers-spanning targeted panels, hybrid capture, library prep reagents, and liquid-handling systems-are doubling down on turnkey workflows that reduce hands-on time and variability. Informatics vendors are racing to package variant calling, annotation, reporting, and quality management into auditable pipelines that plug into laboratory information systems and enterprise data lakes. Meanwhile, contract research organizations and certified sequencing service providers are repositioning as end-to-end partners who can absorb tariff risk, meet data-residency obligations, and deliver validated reports under tight timelines.

Actionable guidance for industry leaders: de-risk supply, accelerate evidence, align compliance, and translate sequencing innovation into outcomes

First, treat tariffs as a constant rather than a shock. Build a rolling 18- to 24-month sourcing plan that incorporates scenario-based landed cost models for instruments, flow cells, and consumables, with explicit assumptions about duty rates, shipping, and installation lead times. Add secondary suppliers for critical consumables-primers and probes, enzymes and buffers, and sequencing kits-and negotiate indexed pricing plus contingency clauses that trigger when tariff bands move. For clinical environments, align safety stocks with accreditation and validation cycles to avoid downtime.

Second, adopt a modality-agnostic technology strategy. Maintain at least two complementary platforms-one short-read, one long-read or nanopore-so that structural variants, repeat expansions, targeted panels, and methylation can be addressed in a single laboratory. Where volumes are variable, consider single-flow-cell or mid-throughput systems for everyday operations, reserving high-throughput instruments for batch runs or service partners. Build library preparation and capture workflows that can be shared across platforms to minimize training overhead and consumable complexity.

Third, accelerate clinical evidence generation linked to reimbursement. If you are pursuing oncology, align tumor profiling to FDA-cleared or approved kits where applicable and build prospective utility studies that show time-to-treatment impact and therapy matching-key levers for payer confidence. For rare disease, partner with centers that can combine long-read genome, methylation, and RNA for challenging cases, and publish turnaround time and diagnostic yield under routine conditions.

Fourth, invest in resilient informatics. Standardize on auditable, version-controlled pipelines with provenance tracking from sample intake to report, and design for multi-cloud or hybrid to manage egress fees and data-localization requirements. In Europe, map your data strategy to the European Health Data Space timelines and roles-trusted data holders, access bodies, and interoperability specs-and ensure patient-facing consent and access controls are ready for cross-border use.

Fifth, future-proof compliance. Even with the U.S. LDT rule vacated and in rollback, maintain device-grade documentation, change control, and complaint handling to preserve optionality should policy swing again. Prepare for possible federal funding restrictions on specified foreign-adversary biotech entities by auditing supplier exposure, documenting alternatives, and communicating with grants offices about procurement policies.

Lastly, start with end-user experience. For hospitals and diagnostic laboratories, design workflows for minimal hands-on time and predictable turnaround, backed by on-site technical support and remote monitoring. For academic and government research institutes and university labs, emphasize openness, data portability, and shared compute resources. For CROs and biopharma, link sequencing outputs to biomarker strategies, companion diagnostic timelines, and regulatory submissions to compress cycle times from discovery to development.

How this executive summary was built: rigorous methodology combining primary insight, regulatory review, and cross-validated secondary intelligence

This executive summary synthesizes insights gathered through a mixed-methods approach designed for depth, triangulation, and traceability. Primary research included structured and semi-structured interviews with sequencing platform owners, clinical laboratory directors, academic core facility leaders, translational researchers, CRO executives, and bioinformatics architects across North America, Europe, and Asia-Pacific. These conversations focused on platform selection criteria, run performance under updated chemistries, validation and accreditation practices, procurement constraints created by tariffs and export controls, and the evolving interface between bioinformatics and electronic health records.

Secondary research concentrated on authoritative and timely sources. Regulatory milestones were verified against official publications and agency communications, including U.S. Food and Drug Administration rulemaking, court decisions, and subsequent agency actions related to laboratory-developed tests; European Commission, Council, and Directorate-General communications on the European Health Data Space; and U.S. trade policy updates via the Office of the United States Trade Representative and executive orders. Company-level developments were corroborated using issuer press releases, investor disclosures, and, where relevant, peer-reviewed literature or conference materials. News coverage from global outlets provided contemporaneous context on policy shifts, trade actions, and market responses.

Data synthesis followed a disciplined process. First, we mapped evidence to a segmentation framework spanning offerings; technology type; sample type; applications; and end users. Next, we normalized terminology across sources to avoid conflation of chemistry, platform, and application claims. Finally, we stress-tested conclusions against counter-examples surfaced in interviews and public datasets. No market sizing, share, or forecast figures are presented here; instead, the focus is on qualitative insights with operational implications.

The result is a perspective designed to be both current and durable. Where policies or litigation remain in motion, we anchored statements to dated sources and avoided over-extrapolation. Where technology claims could not be triangulated to independent datasets, we framed them as vendor-reported and evaluated them in the context of end-user experience. This ensures that recommendations can inform decisions now and remain adaptable as new data emerge.

Bringing the narrative together: why sequencing is entering a durable utility phase and how to invest wisely despite volatility and policy shifts

DNA sequencing is entering a durable utility phase. The science has matured to the point where platforms, chemistries, and informatics can be assembled into validated workflows that answer clinical and research questions with speed and accuracy once thought unattainable. Long-read modalities have earned a place alongside short reads; nanopore platforms have expanded beyond field work into regulated workflows; and comprehensive genomic profiling has crossed a regulatory milestone that enables decentralization of oncology testing.

Yet, the operational context is more volatile. Tariffs, export controls, and geopolitical actions have injected persistent uncertainty into cost structures and availability, while data-governance regimes and evolving rules-some advancing, some retreating-require attention to compliance by design. The organizations that will thrive are those that treat supply chain resilience, informatics governance, and clinical evidence as strategic assets, not afterthoughts.

Against this backdrop, leadership teams should move decisively. Adopt a modality-agnostic portfolio to cover the full spectrum of genetic and epigenetic variation. Build informatics that is auditable, portable, and aligned to regional data rules. Prepare for tariff-driven volatility with indexed contracts and multi-sourcing. And, most importantly, translate sequencing into outcomes by investing in the studies, partnerships, and training that deliver answers for patients, growers, public-health officials, and investigators. The opportunity is real and present; the winners will be those who operationalize it with foresight and discipline.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Sequencing Market, by Offerings

  • 8.1. Consumables & Reagents
    • 8.1.1. Enzymes & Buffers
    • 8.1.2. Primers & Probes
    • 8.1.3. Sequencing Kits
  • 8.2. Instruments & Platforms
    • 8.2.1. DNA Sequencers
    • 8.2.2. Library Preparation Systems
    • 8.2.3. PCR Machines
    • 8.2.4. Flow Cell & Cartridge Hardware
  • 8.3. Services
    • 8.3.1. Contract Sequencing
    • 8.3.2. Bioinformatics & Data Analysis Services
    • 8.3.3. Technical Support and Maintenance
  • 8.4. Software

9. DNA Sequencing Market, by Technology Type

  • 9.1. Next-Generation Sequencing (NGS)
    • 9.1.1. Sequencing by Synthesis
    • 9.1.2. Nanopore Sequencing
    • 9.1.3. Ion Semiconductor Sequencing
  • 9.2. Sanger Sequencing
  • 9.3. Third-Generation Sequencing (TGS)
  • 9.4. Epigenetic Sequencing
    • 9.4.1. Bisulfite Sequencing
    • 9.4.2. ChIP sequencing

10. DNA Sequencing Market, by Sample Type

  • 10.1. Human Samples
    • 10.1.1. Blood
    • 10.1.2. Saliva & Buccal Swab
    • 10.1.3. Urine
    • 10.1.4. Cell-Free DNA
    • 10.1.5. Tissue
    • 10.1.6. Plasma
  • 10.2. Animal Samples
  • 10.3. Plant Samples
    • 10.3.1. Leaf
    • 10.3.2. Root
    • 10.3.3. Seed
  • 10.4. Microbial Samples
    • 10.4.1. Bacteria
    • 10.4.2. Viruses
    • 10.4.3. Fungi
    • 10.4.4. Archaea
  • 10.5. Environmental Samples

11. DNA Sequencing Market, by Application

  • 11.1. Clinical Diagnostics
    • 11.1.1. Oncology
    • 11.1.2. Infectious Disease Diagnosis
    • 11.1.3. Rare Disease & Genetic Disorder Testing
    • 11.1.4. Reproductive Health & Prenatal Testing
    • 11.1.5. Newborn Screening
  • 11.2. Research Applications
    • 11.2.1. Genomics & Transcriptomics
    • 11.2.2. Functional Genomics
    • 11.2.3. Epigenetics Research
  • 11.3. Drug Discovery & Development
    • 11.3.1. Biomarker Discovery
    • 11.3.2. Companion Diagnostics
    • 11.3.3. Target Identification & Validation
  • 11.4. Agrigenomics
    • 11.4.1. Plant Breeding & Trait Discovery
    • 11.4.2. Crop Pathogen Surveillance
  • 11.5. Forensics & Security
    • 11.5.1. Human Identification
    • 11.5.2. Criminal Investigation
    • 11.5.3. Disaster Victim Identification
  • 11.6. Environmental & Metagenomic Studies

12. DNA Sequencing Market, by End User

  • 12.1. Academic & Research Institutions
    • 12.1.1. Government Research Institutes
    • 12.1.2. University Labs
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Diagnostic Laboratories
  • 12.4. Pharmaceutical & Biotechnology Companies

13. DNA Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States DNA Sequencing Market

17. China DNA Sequencing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 10x Genomics, Inc.
  • 18.6. Abbott Laboratories
  • 18.7. AbbVie Inc.
  • 18.8. Agilent Technologies, Inc.
  • 18.9. Azenta, Inc.
  • 18.10. Becton, Dickinson and Company
  • 18.11. BGI Genomics Co., Ltd.
  • 18.12. Bio-Rad Laboratories, Inc.
  • 18.13. BioChain Institute Inc.
  • 18.14. Charles River Laboratories International, Inc.
  • 18.15. Danaher Corporation
  • 18.16. Eppendorf SE
  • 18.17. Eurofins Scientific SE
  • 18.18. F. Hoffmann-La Roche Ltd.
  • 18.19. Genomics England
  • 18.20. Genscript Biotech Corporation
  • 18.21. Illumina, Inc.
  • 18.22. Johnson & Johnson Services, Inc.
  • 18.23. Laboratory Corporation of America Holdings
  • 18.24. Macrogen Inc.
  • 18.25. Merck KGaA
  • 18.26. Myriad Genetics, Inc.
  • 18.27. Novartis AG
  • 18.28. Novogene Co, Ltd.
  • 18.29. Oxford Nanopore Technologies PLC
  • 18.30. Pacific Biosciences of California, Inc.
  • 18.31. PerkinElmer, Inc.
  • 18.32. QIAGEN N.V.
  • 18.33. Sartorius AG
  • 18.34. Shimadzu Corporation
  • 18.35. Thermo Fisher Scientific Inc.
  • 18.36. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENZYMES & BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA SEQUENCING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA SEQUENCING MARKET SIZE, BY DNA SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA SEQUENCING MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA SEQUENCING MARKET SIZE, BY FLOW CELL & CARTRIDGE HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA SEQUENCING MARKET SIZE, BY FLOW CELL & CARTRIDGE HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA SEQUENCING MARKET SIZE, BY FLOW CELL & CARTRIDGE HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNICAL SUPPORT AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNICAL SUPPORT AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNICAL SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA SEQUENCING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA SEQUENCING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA SEQUENCING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEQUENCING BY SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA SEQUENCING MARKET SIZE, BY NANOPORE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA SEQUENCING MARKET SIZE, BY NANOPORE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA SEQUENCING MARKET SIZE, BY NANOPORE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA SEQUENCING MARKET SIZE, BY ION SEMICONDUCTOR SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA SEQUENCING MARKET SIZE, BY ION SEMICONDUCTOR SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA SEQUENCING MARKET SIZE, BY ION SEMICONDUCTOR SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA SEQUENCING MARKET SIZE, BY THIRD-GENERATION SEQUENCING (TGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA SEQUENCING MARKET SIZE, BY BISULFITE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA SEQUENCING MARKET SIZE, BY BISULFITE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA SEQUENCING MARKET SIZE, BY BISULFITE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA SEQUENCING MARKET SIZE, BY CHIP SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA SEQUENCING MARKET SIZE, BY CHIP SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA SEQUENCING MARKET SIZE, BY CHIP SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA SEQUENCING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DNA SEQUENCING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA SEQUENCING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DNA SEQUENCING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA SEQUENCING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DNA SEQUENCING MARKET SIZE, BY SALIVA & BUCCAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DNA SEQUENCING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DNA SEQUENCING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DNA SEQUENCING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DNA SEQUENCING MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DNA SEQUENCING MARKET SIZE, BY CELL-FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DNA SEQUENCING MARKET SIZE, BY CELL-FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DNA SEQUENCING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DNA SEQUENCING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DNA SEQUENCING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANIMAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANIMAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DNA SEQUENCING MARKET SIZE, BY ANIMAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DNA SEQUENCING MARKET SIZE, BY LEAF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DNA SEQUENCING MARKET SIZE, BY LEAF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DNA SEQUENCING MARKET SIZE, BY LEAF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DNA SEQUENCING MARKET SIZE, BY ROOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DNA SEQUENCING MARKET SIZE, BY ROOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DNA SEQUENCING MARKET SIZE, BY ROOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DNA SEQUENCING MARKET SIZE, BY SEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DNA SEQUENCING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DNA SEQUENCING MARKET SIZE, BY BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DNA SEQUENCING MARKET SIZE, BY BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DNA SEQUENCING MARKET SIZE, BY VIRUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DNA SEQUENCING MARKET SIZE, BY VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DNA SEQUENCING MARKET SIZE, BY VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DNA SEQUENCING MARKET SIZE, BY ARCHAEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DNA SEQUENCING MARKET SIZE, BY ARCHAEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DNA SEQUENCING MARKET SIZE, BY ARCHAEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DNA SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DNA SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DNA SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DNA SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA SEQUENCING MARKET SIZE, BY RARE DISEASE & GENETIC DISORDER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DNA SEQUENCING MARKET SIZE, BY RARE DISEASE & GENETIC DISORDER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA SEQUENCING MARKET SIZE, BY RARE DISEASE & GENETIC DISORDER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DNA SEQUENCING MARKET SIZE, BY REPRODUCTIVE HEALTH & PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DNA SEQUENCING MARKET SIZE, BY REPRODUCTIVE HEALTH & PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DNA SEQUENCING MARKET SIZE, BY REPRODUCTIVE HEALTH & PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DNA SEQUENCING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENOMICS & TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENOMICS & TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DNA SEQUENCING MARKET SIZE, BY GENOMICS & TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL DNA SEQUENCING MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETICS RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETICS RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL DNA SEQUENCING MARKET SIZE, BY EPIGENETICS RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL DNA SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL DNA SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL DNA SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL DNA SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL DNA SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL DNA SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL DNA SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT BREEDING & TRAIT DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT BREEDING & TRAIT DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL DNA SEQUENCING MARKET SIZE, BY PLANT BREEDING & TRAIT DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL DNA SEQUENCING MARKET SIZE, BY CROP PATHOGEN SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL DNA SEQUENCING MARKET SIZE, BY CROP PATHOGEN SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL DNA SEQUENCING MARKET SIZE, BY CROP PATHOGEN SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL DNA SEQUENCING MARKET SIZE, BY HUMAN IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL DNA SEQUENCING MARKET SIZE, BY CRIMINAL INVESTIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DNA SEQUENCING MARKET SIZE, BY CRIMINAL INVESTIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL DNA SEQUENCING MARKET SIZE, BY CRIMINAL INVESTIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL DNA SEQUENCING MARKET SIZE, BY DISASTER VICTIM IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL DNA SEQUENCING MARKET SIZE, BY DISASTER VICTIM IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL DNA SEQUENCING MARKET SIZE, BY DISASTER VICTIM IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL & METAGENOMIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL & METAGENOMIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL DNA SEQUENCING MARKET SIZE, BY ENVIRONMENTAL & METAGENOMIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL DNA SEQUENCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL DNA SEQUENCING MARKET SIZE, BY UNIVERSITY LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL DNA SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL DNA SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL DNA SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY HUMAN SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY PLANT SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY MICROBIAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY AGRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY FORENSICS & SECURITY, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DNA SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE DNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE DNA SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPE DNA SEQUENCING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPE DNA SEQUENCING MARKET SIZE, BY INSTRUMENTS & PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPE DNA SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPE DNA SEQUENCING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPE DNA SEQUENCING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 316. EUROPE DNA SEQUENCING MARKET SIZE, BY EPIGENETIC SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPE DNA SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPE DNA SEQUENCING MARKET SIZE, BY HUMAN SA